10.73
-0.02(-0.19%)
Currency In USD
| Previous Close | 10.75 |
| Open | 10.79 |
| Day High | 11.15 |
| Day Low | 10.69 |
| 52-Week High | 11.15 |
| 52-Week Low | 5.92 |
| Volume | 3.77M |
| Average Volume | 4.62M |
| Market Cap | 2.25B |
| PE | -41.27 |
| EPS | -0.26 |
| Moving Average 50 Days | 8.68 |
| Moving Average 200 Days | 8.06 |
| Change | -0.02 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $875.92 as of June 03, 2025 at a share price of $10.73. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $2,384.44 as of June 03, 2025 at a share price of $10.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) w
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
GlobeNewswire Inc.
May 30, 2025 11:00 AM GMT
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of lifeRESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced ne
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
GlobeNewswire Inc.
May 16, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE s